Chugai Pharmaceutical Company Description
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.
It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases.
Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia.
The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
| Country | United States |
| Founded | 1925 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 5,026 |
| CEO | Osamu Okuda |
Contact Details
Address: Nihonbashi Mitsui Tower Chuo Japan | |
| Phone | 81 3 3281 6611 |
Stock Details
| Ticker Symbol | CHGCF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | JP3519400000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Osamu Okuda | President, Chief Executive Officer and Chairman |
| Iwaaki Taniguchi | Executive Vice President, Head of Finance Supervisory Division, Chief Financial Officer and Director |
| Toshiya Sasai | Executive of Investor Relations Group and Corporate Communications Department |
| Junichi Takano | Head of Marketing and Sales Division |
| Shinji Hidaka | Executive Vice President |
| Katsuhiro Hara | Strategic Leader |
| Dr. Takaki Koga | Polivy Lifecycle Leader |
| Hideto Kodaira | Evrysdi Lifecycle Leader |
| Dr. Shinta Kobayashi | DONQ52 Global Project Leader |
| Takei Kake | GYM329 Global Project Leader |